Stoke Therapeutics (NASDAQ:STOK) Insider Sells $54,891.10 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 1,795 shares of Stoke Therapeutics stock in a transaction on Monday, June 1st. The shares were sold at an average price of $30.58, for a total transaction of $54,891.10. Following the completion of the sale, the insider owned 34,826 shares in the company, valued at approximately $1,064,979.08. This represents a 4.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Barry Ticho also recently made the following trade(s):

• On Wednesday, March 18th, Barry Ticho sold 6,686 shares of Stoke Therapeutics stock. The shares were sold at an average price of $31.34, for a total transaction of $209,539.24.
• On Tuesday, March 17th, Barry Ticho sold 6,164 shares of Stoke Therapeutics stock. The shares were sold at an average price of $33.01, for a total transaction of $203,473.64.
• On Thursday, March 19th, Barry Ticho sold 1,461 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.99, for a total transaction of $43,815.39.

Stoke Therapeutics Stock Performance

Shares of NASDAQ STOK opened at $30.01 on Friday. The company has a market cap of $1.87 billion, a P/E ratio of -10.68 and a beta of 1.17. The firm’s fifty day moving average is $32.58 and its two-hundred day moving average is $32.33. Stoke Therapeutics, Inc. has a 52-week low of $10.90 and a 52-week high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.01. The company had revenue of $6.23 million for the quarter, compared to the consensus estimate of $6.48 million. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. As a group, analysts forecast that Stoke Therapeutics, Inc. will post -3.22 EPS for the current fiscal year.

Analyst Ratings Changes

STOK has been the topic of a number of research reports. BTIG Research reiterated a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a report on Monday, May 11th. Canaccord Genuity Group lifted their price target on shares of Stoke Therapeutics from $36.00 to $60.00 and gave the company a “buy” rating in a report on Friday, March 20th. Wall Street Zen downgraded shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Weiss Ratings cut shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Finally, Wedbush lifted their price objective on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 17th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $41.83.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in STOK. Janus Henderson Group PLC grew its stake in shares of Stoke Therapeutics by 333.8% in the 4th quarter. Janus Henderson Group PLC now owns 1,450,933 shares of the company’s stock worth $46,031,000 after buying an additional 1,116,452 shares in the last quarter. State Street Corp boosted its stake in shares of Stoke Therapeutics by 75.2% during the 4th quarter. State Street Corp now owns 2,498,049 shares of the company’s stock worth $79,288,000 after purchasing an additional 1,072,176 shares during the period. Corient Private Wealth LLC bought a new position in Stoke Therapeutics during the 2nd quarter valued at about $7,489,000. Troluce Capital Advisors LLC bought a new position in Stoke Therapeutics during the 1st quarter valued at about $21,255,000. Finally, BVF Inc. IL grew its holdings in Stoke Therapeutics by 36.7% during the 4th quarter. BVF Inc. IL now owns 2,265,674 shares of the company’s stock valued at $71,912,000 after purchasing an additional 608,578 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.